Eli Lilly (LLY) concluded the recent trading session at $796.03, signifying a -0.44% move from its prior day's close.

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

A national medical firm has announced it will launch a $3 billion expansion of its Kenosha County facility and will bring 750 ...

Fox News senor medical analyst Dr. Marc Siegel weighs in on the FDA weighing a crackdown on food dye, major food companies ...

With a positive phase 3 trial in chronic lymphocytic leukemia (CLL), Eli Lilly hopes to convert Jaypirca’s unique accelerated ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

Lilly’s investment and the UK government’s strategic support for life sciences and healthcare represent a pivotal moment for the industry.

The healthcare industry is set for growth due to the growing demand for quality treatments and ongoing progress in medical ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc.

Lilly's rival Danish firm Novo Nordisk is also working to bring its obesity drug Wegovy (Semaglutide) to India soon, and ...

The company also raised its quarterly dividend 15% amid rapid growth fueled in part by the blockbuster weight-loss drug ...